Completed OBSERVATIONAL NCT03401034

Influence of Lifestyle, Inflammatory Biomarkers, and Genetic Factors on Long-term Breast Cancer Prognosis

The Influence of Lifestyle and Genetic Risk Factors, Circulating Inflammatory Biomarkers and Menopausal Hormone Therapy on Long-term Prognosis After Postmenopausal Breast Cancer

Sponsor: German Cancer Research Center

Conditions Breast Cancer Breast Cancer Mortality Breast Cancer Survival Genetic Factors Hormone Therapy Inflammation Inflammatory Biomarkers Lifestyle Phytoestrogens Postmenopausal Breast Cancer

Updated 9 times since 2018 Last updated: Jan 15, 2018 Started: Aug 1, 2002 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and Breast Cancer Mortality and is currently completed. German Cancer Research Center leads this study, which shows 9 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 4 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Feb 2018 — Apr 2018 [monthly]

Completed NA

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German Cancer Research Center

Data source: German Cancer Research Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.